fbpx Skip to main content

Member's Profile

Blade Therapeutics

442 Littlefield Avenue
South San Francisco,   CA
United States
Membership Info
Membership Type: Industry
Membership Since: 2016
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Blade Therapeutics
Biotech Company

Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade’s lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases. BLD-2660 is in a Phase I, healthy volunteer, dose escalation study in Australia, and the Company plans to submit an Investigational New Drug (IND) application to the U.S. FDA and initiate a Phase II trial in patients with liver fibrosis by year-end 2019. Blade has assembled a critical mass of anti-fibrotic drug development expertise within its top-tier leadership team and a world-class network of advisors. Lead investors in Blade include MPM Capital, Deerfield, Pfizer Ventures, One Ventures, Osage Partners, Bristol-Myers Squibb and Novartis Institute of Biomedical Research.

Related News
No related news posted by this Member